|Articles|June 1, 2002
Latanoprost plus brimonidine controls IOP
Austin, TX-Patients who need more than one ocular hypotensive agent to achieve low IOP may benefit more from a regimen of latanoprost (Xalatan, Pharmacia) and adjunctive brimonidine (Alphagan, Allergan) than from dual therapy with latanoprost and timolol, according to a recent study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT completes enrollment in 4FRONT-1, phase 3 trial of 4D-150 in AMD
2
Angiogenesis 2026: Continuous AI severity scoring could transform AMD monitoring
3
SparingVision completes PRODYGY trial patient dosing with SPVN06
4
Q&A: Optimizing the ocular surface for light adjustable lens technology
5
























